HKSE:01877 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:01877 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Dec. 2024, Shanghai Junshi Biosciences Co paid HK$0 Mil more to buy back shares than it received from issuing new shares. It received HK$157 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0 Mil from paying cash dividends to shareholders. It spent HK$33 Mil on other financial activities. In all, Shanghai Junshi Biosciences Co earned HK$125 Mil on financial activities for the three months ended in Dec. 2024.
The historical data trend for Shanghai Junshi Biosciences Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Cash Flow from Financing | Get a 7-Day Free Trial |
![]() |
5,231.93 | 3,264.05 | 5,184.92 | 744.91 | 1,085.65 |
Shanghai Junshi Biosciences Co Quarterly Data | ||||||||||||||||||||
Dec16 | Dec17 | Jun18 | Dec18 | Jun19 | Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Cash Flow from Financing | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
262.34 | 1,325.11 | -517.91 | 177.57 | 124.71 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Shanghai Junshi Biosciences Co's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing | (A: Dec. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | -4.272 | + | 1209.385 | + | 0 | + | 0 | + | -77.18 |
= | 1,128 |
Shanghai Junshi Biosciences Co's Cash from Financing for the quarter that ended in Dec. 2024 is:
Cash Flow from Financing | (Q: Dec. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | 157.418 | + | 0 | + | 0 | + | -32.706 |
= | 125 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1,109 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (HKSE:01877) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Shanghai Junshi Biosciences Co's issuance of stock for the three months ended in Dec. 2024 was HK$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Shanghai Junshi Biosciences Co's repurchase of stock for the three months ended in Dec. 2024 was HK$0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Shanghai Junshi Biosciences Co's net issuance of debt for the three months ended in Dec. 2024 was HK$157 Mil. Shanghai Junshi Biosciences Co received HK$157 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Shanghai Junshi Biosciences Co's net issuance of preferred for the three months ended in Dec. 2024 was HK$0 Mil. Shanghai Junshi Biosciences Co paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Shanghai Junshi Biosciences Co's cash flow for dividends for the three months ended in Dec. 2024 was HK$0 Mil. Shanghai Junshi Biosciences Co received HK$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Shanghai Junshi Biosciences Co's other financing for the three months ended in Dec. 2024 was HK$-33 Mil. Shanghai Junshi Biosciences Co spent HK$33 Mil on other financial activities.
Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Gic (ventures) Pte. Ltd. | 2201 Interest of corporation controlled by you | |
Gic Special Investments Private Limited | 2102 Investment manager | |
Gic Private Limited | 2201 Interest of corporation controlled by you | |
Highbury Investment Pte Ltd | 2101 Beneficial owner | |
Jovial Champion Investments Limited | 2201 Interest of corporation controlled by you | |
Gong Ruilin | 2202 Interest of your spouse | |
Vistra Trust (singapore) Pte. Limited | 2201 Interest of corporation controlled by you | |
Lvc Holdings Limited | 2201 Interest of corporation controlled by you | |
Lvc Management Holdings Limited | 2201 Interest of corporation controlled by you | |
Lvc Innovate Limited | 2201 Interest of corporation controlled by you | |
Lin Lijun | 2307 Founder of a discretionary trust who can infl | |
Lvc Renaissance Fund Lp | 2101 Beneficial owner | |
Lvc Renaissance Limited | 2201 Interest of corporation controlled by you | |
Loyal Valley Innovation Capital (hk) Limited | 2201 Interest of corporation controlled by you | |
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si | 2201 Interest of corporation controlled by you |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.